Hennion & Walsh Asset Management, Inc. Rapt Therapeutics, Inc. Transaction History
Hennion & Walsh Asset Management, Inc.
- $1.89 Billion
- Q2 2024
A detailed history of Hennion & Walsh Asset Management, Inc. transactions in Rapt Therapeutics, Inc. stock. As of the latest transaction made, Hennion & Walsh Asset Management, Inc. holds 48,525 shares of RAPT stock, worth $97,050. This represents 0.01% of its overall portfolio holdings.
Number of Shares
48,525
Previous 44,701
8.55%
Holding current value
$97,050
Previous $401,000
63.09%
% of portfolio
0.01%
Previous 0.02%
Shares
5 transactions
Others Institutions Holding RAPT
# of Institutions
126Shares Held
29.1MCall Options Held
905KPut Options Held
592K-
Vanguard Group Inc Valley Forge, PA3.11MShares$6.22 Million0.0% of portfolio
-
Column Group LLC San Francisco, CA2.68MShares$5.36 Million11.48% of portfolio
-
Black Rock Inc. New York, NY2.44MShares$4.88 Million0.0% of portfolio
-
Kingdon Capital Management, L.L.C. New York, NY1.73MShares$3.45 Million0.61% of portfolio
-
Ponoi Management, LLC San Francisco, CA1.6MShares$3.2 Million52.54% of portfolio
About RAPT Therapeutics, Inc.
- Ticker RAPT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 29,656,600
- Market Cap $59.3M
- Description
- RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that se...